Skip to main content
Loading

Solid Tumor Advances: T-Cell Engagers, Radioligands, and More

February 11, 2025
Astor
Oncology remains one of the top therapeutic areas garnering investor interest, and scientific advances are yielding new approaches that are showing sometimes game-changing clinical promise in treating solid tumors. This session will discuss the promising modalities that are captivating investors and physicians alike​.
Moderator
Kelly Shi, Senior Vice President, Senior Research Analyst in Biotechnology - Jefferies
Speakers
Andrew Cittadine, Chief Operating Officer - Monopar Therapeutics
Isan Chen, Co-founder, President and Chief Executive Officer - MBrace Therapeutics, Inc.
William Ho, President, CEO, and Co-founder - IN8bio
Rachel Humphrey, Founding Chief Executive Officer - Normunity
Steven Rosen, Executive Vice President - City of Hope
View all 2025 Program
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors